Biotech Values

[zipjet]

DD - declare the winner if you like.

You have promoted the proposition that sell-side analysts all know that tL is DoA. It fits with your views.

I am agnostic on that proposition. It may be true or not.

Yet, you continue to argue about the dot on the "i".

The issue of some utility is the inference that may be drawn from MNTA selling closer to the valuation that one would expect IF tL is approved, than the valuation that it would carry IF tL is DoA.

Fill in the blanks:

A) MNTA value if tL is DoA ______

B) MNTA value if tL will be approved in 2011 _________

MNTA close 17.43

My answers: A) 12-15 B) 40-55

I would suggest that you have some inherent hostility to the notion that Teva’s Lovenox is not going to get approved fairly soon, perhaps because the thesis is at odds with your covered-call posture in MNTA. Your posts on this subject have been bizarre, to say the least, and have caused several posters to question your sanity in private messages to me.

You do like to attack the person. Others can question my sanity until we get a psychiatrist to evaluate me. I for one would like to know if I am sane. I am very grateful to Harvey a 6' pooka*.



ij


*